lobbying_filings_raw: d2a6ee41-4e40-4b98-97aa-13c8a2c74e55
This data as json
| filing_uuid | filing_type | registrant_id | registrant_name | client_id | client_name | filing_year | filing_period | received_date | amount_reported | is_amendment | is_no_activity | is_termination | raw_json |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| d2a6ee41-4e40-4b98-97aa-13c8a2c74e55 | Q3 | 29403 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 134698 | CONSUMER HEALTHCARE PRODUCTS ASSOCIATION | 2013 | third_quarter | 2013-10-17T13:54:35.443000-04:00 | 280000.0 | 0 | 0 | 0 | {"url": "https://lda.senate.gov/api/v1/filings/d2a6ee41-4e40-4b98-97aa-13c8a2c74e55/", "filing_uuid": "d2a6ee41-4e40-4b98-97aa-13c8a2c74e55", "filing_type": "Q3", "filing_type_display": "3rd Quarter - Report", "filing_year": 2013, "filing_period": "third_quarter", "filing_period_display": "3rd Quarter (July 1 - Sep 30)", "filing_document_url": "https://lda.senate.gov/filings/public/filing/d2a6ee41-4e40-4b98-97aa-13c8a2c74e55/print/", "filing_document_content_type": "text/html", "income": null, "expenses": "280000.00", "expenses_method": "a", "expenses_method_display": "Method A - Reporting amounts using LDA definitions only", "posted_by_name": "David C. Spangler, Senior Vice President, Policy, and General Counsel & Secretary", "dt_posted": "2013-10-17T13:54:35.443000-04:00", "termination_date": null, "registrant_country": "United States of America", "registrant_ppb_country": null, "registrant_address_1": "900 19TH STREET, NW #700", "registrant_address_2": null, "registrant_different_address": false, "registrant_city": "WASHINGTON", "registrant_state": "DC", "registrant_zip": "20006", "registrant": {"id": 29403, "url": "https://lda.senate.gov/api/v1/registrants/29403/", "house_registrant_id": 31286, "name": "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", "description": null, "address_1": "1625 Eye Street NW", "address_2": "Suite 600", "address_3": null, "address_4": null, "city": "WASHINGTON", "state": "DC", "state_display": "District of Columbia", "zip": "20006", "country": "US", "country_display": "United States of America", "ppb_country": "US", "ppb_country_display": "United States of America", "contact_name": "DAVID SPANGLER", "contact_telephone": "+1 202-429-9260", "dt_updated": "2026-01-15T16:02:44.446638-05:00"}, "client": {"id": 134698, "url": "https://lda.senate.gov/api/v1/clients/134698/", "client_id": 12, "name": "CONSUMER HEALTHCARE PRODUCTS ASSOCIATION", "general_description": null, "client_government_entity": false, "client_self_select": true, "state": "DC", "state_display": "District of Columbia", "country": "US", "country_display": "United States of America", "ppb_state": "DC", "ppb_state_display": "District of Columbia", "ppb_country": "US", "ppb_country_display": "United States of America", "effective_date": "2007-08-08"}, "lobbying_activities": [{"general_issue_code": "CHM", "general_issue_code_display": "Chemicals/Chemical Industry", "description": "Toxic Substances Control Act of 1976 (P.L. 94-469)S. 1009 - Chemical Safety Improvement Act. Modernize and update the Toxic Substances Control Act of 1976 (TSCA; P.L. 94-469) by allowing the Environmental Protection Agency (EPA) to prioritize consideration of chemicals based on risk and set minimum federal standards for chemical regulation; all sections.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 56148, "prefix": null, "prefix_display": null, "first_name": "JOHN", "nickname": null, "middle_name": null, "last_name": "GAY", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 57014, "prefix": "mrs", "prefix_display": "MRS.", "first_name": "LINDSAY", "nickname": null, "middle_name": "A", "last_name": "MORRIS", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 52622, "prefix": null, "prefix_display": null, "first_name": "TRAVIS", "nickname": null, "middle_name": null, "last_name": "GIBBONS", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 19, "name": "Office of Natl Drug Control Policy (NDCP)"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "ALC", "general_issue_code_display": "Alcohol and Drug Abuse", "description": "DextromethorphanDextromethorphan - legislation related to reducing incidents of abuse of a common ingredient in over-the-counter cough and cold medications: dextromethorphan (Preventing Abuse of Cough Treatments Act, S. 644, all sections).", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 56148, "prefix": null, "prefix_display": null, "first_name": "JOHN", "nickname": null, "middle_name": null, "last_name": "GAY", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 57014, "prefix": "mrs", "prefix_display": "MRS.", "first_name": "LINDSAY", "nickname": null, "middle_name": "A", "last_name": "MORRIS", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 52622, "prefix": null, "prefix_display": null, "first_name": "TRAVIS", "nickname": null, "middle_name": null, "last_name": "GIBBONS", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 19, "name": "Office of Natl Drug Control Policy (NDCP)"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "TAX", "general_issue_code_display": "Taxation/Internal Revenue Code", "description": "Flexible spending arrangements (FSA) and health savings accounts (HSA)H.R. 2835/Potential Senate Companion Bill - Restoring Access to Medication Act. Repeals prohibition in Patient Protection and Affordable Care Act (P.L. 111-148, P.L. 111-152) against use of flexible spending arrangement (FSA) and health savings account (HSA) funds on over-the-counter medications; all sections.\n\nH.R. 1248/S. 610 - Family Health Care Flexibility Act. Would also repeal prohibition in Patient Protection and Affordable Care Act (P.L. 111-148, P.L. 111-152) against use of flexible spending arrangement (FSA) and health savings account (HSA) funds on over-the-counter medications; all sections.", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 56148, "prefix": null, "prefix_display": null, "first_name": "JOHN", "nickname": null, "middle_name": null, "last_name": "GAY", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 57014, "prefix": "mrs", "prefix_display": "MRS.", "first_name": "LINDSAY", "nickname": null, "middle_name": "A", "last_name": "MORRIS", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 52622, "prefix": null, "prefix_display": null, "first_name": "TRAVIS", "nickname": null, "middle_name": null, "last_name": "GIBBONS", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 19, "name": "Office of Natl Drug Control Policy (NDCP)"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "FOO", "general_issue_code_display": "Food Industry (safety, labeling, etc.)", "description": "Dietary SupplementsReintroduction of S. 3431 - Designer Anabolic Steroid Control Act (DASCA, 112th Congress). Food and Drug Administration (FDA) regulation of anabolic steroids; all sections.\n\nReintroduction of H.R. 1364 - Free Speech About Science Act of 2011 (112th Congress). Food and Drug Administration (FDA) regulation of dietary supplements labeling; all sections.\n\nFood and Drug Administration (FDA) draft \"Guidance for Industry: New Dietary Ingredient Notifications and Related Issues.\"", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 56148, "prefix": null, "prefix_display": null, "first_name": "JOHN", "nickname": null, "middle_name": null, "last_name": "GAY", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 57014, "prefix": "mrs", "prefix_display": "MRS.", "first_name": "LINDSAY", "nickname": null, "middle_name": "A", "last_name": "MORRIS", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 52622, "prefix": null, "prefix_display": null, "first_name": "TRAVIS", "nickname": null, "middle_name": null, "last_name": "GIBBONS", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 19, "name": "Office of Natl Drug Control Policy (NDCP)"}, {"id": 1, "name": "SENATE"}]}, {"general_issue_code": "PHA", "general_issue_code_display": "Pharmacy", "description": "PseudoephedrinePseudoephedrine - potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number).", "foreign_entity_issues": "", "lobbyists": [{"lobbyist": {"id": 56148, "prefix": null, "prefix_display": null, "first_name": "JOHN", "nickname": null, "middle_name": null, "last_name": "GAY", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 57014, "prefix": "mrs", "prefix_display": "MRS.", "first_name": "LINDSAY", "nickname": null, "middle_name": "A", "last_name": "MORRIS", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}, {"lobbyist": {"id": 52622, "prefix": null, "prefix_display": null, "first_name": "TRAVIS", "nickname": null, "middle_name": null, "last_name": "GIBBONS", "suffix": null, "suffix_display": null}, "covered_position": null, "new": false}], "government_entities": [{"id": 135, "name": "Food & Drug Administration (FDA)"}, {"id": 2, "name": "HOUSE OF REPRESENTATIVES"}, {"id": 19, "name": "Office of Natl Drug Control Policy (NDCP)"}, {"id": 1, "name": "SENATE"}]}], "conviction_disclosures": [], "foreign_entities": [], "affiliated_organizations": []} |